BRPI0914942A2 - Compostos de oxindol - Google Patents
Compostos de oxindolInfo
- Publication number
- BRPI0914942A2 BRPI0914942A2 BRPI0914942-2A BRPI0914942A BRPI0914942A2 BR PI0914942 A2 BRPI0914942 A2 BR PI0914942A2 BR PI0914942 A BRPI0914942 A BR PI0914942A BR PI0914942 A2 BRPI0914942 A2 BR PI0914942A2
- Authority
- BR
- Brazil
- Prior art keywords
- oxindole compounds
- oxindole
- compounds
- Prior art date
Links
- 125000004095 oxindolyl group Chemical class N1(C(CC2=CC=CC=C12)=O)* 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7709108P | 2008-06-30 | 2008-06-30 | |
| US15642609P | 2009-02-27 | 2009-02-27 | |
| US18009509P | 2009-05-20 | 2009-05-20 | |
| PCT/US2009/049318 WO2010002933A1 (en) | 2008-06-30 | 2009-06-30 | Oxindole compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0914942A2 true BRPI0914942A2 (pt) | 2015-08-11 |
Family
ID=41466309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0914942-2A BRPI0914942A2 (pt) | 2008-06-30 | 2009-06-30 | Compostos de oxindol |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US8124649B2 (pt) |
| EP (1) | EP2307421A4 (pt) |
| JP (1) | JP2011526917A (pt) |
| KR (1) | KR20110025996A (pt) |
| CN (1) | CN102137866A (pt) |
| AU (1) | AU2009267048A1 (pt) |
| BR (1) | BRPI0914942A2 (pt) |
| CA (1) | CA2729745A1 (pt) |
| IL (1) | IL210355A0 (pt) |
| MX (1) | MX2011000150A (pt) |
| WO (1) | WO2010002933A1 (pt) |
| ZA (1) | ZA201100539B (pt) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9090593B2 (en) | 2010-12-09 | 2015-07-28 | Amgen Inc. | Bicyclic compounds as Pim inhibitors |
| CN102688234B (zh) * | 2011-03-21 | 2015-07-29 | 华东理工大学 | 吲哚酮衍生物作为rsk2抑制剂的合成与应用 |
| CA2830780A1 (en) | 2011-03-22 | 2012-09-27 | Amgen Inc. | Azole compounds as pim inhibitors |
| CN103509009A (zh) * | 2012-06-21 | 2014-01-15 | 中国科学院上海药物研究所 | 2-取代-5-苯基呋喃类化合物、其制备方法、药物组合物及其用途 |
| EP2943485B1 (en) | 2013-01-14 | 2017-09-20 | Incyte Holdings Corporation | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors |
| ME03780B (me) | 2013-01-15 | 2021-04-20 | Incyte Holdings Corp | Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze |
| TW201605866A (zh) | 2013-08-23 | 2016-02-16 | 英塞特公司 | 可用作ｐｉｍ激酶抑制劑之呋喃并－及噻吩并－吡啶甲醯胺化合物 |
| WO2016010897A1 (en) | 2014-07-14 | 2016-01-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
| CA2988147C (en) | 2015-06-03 | 2023-06-13 | Bristol-Myers Squibb Company | 4-hydroxy-3-(heteroaryl)pyridine-2-one apj agonists for use in the treatment of cardiovascular disorders |
| AR105967A1 (es) | 2015-09-09 | 2017-11-29 | Incyte Corp | Sales de un inhibidor de pim quinasa |
| WO2017059251A1 (en) | 2015-10-02 | 2017-04-06 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| EP3187496A1 (de) * | 2015-12-30 | 2017-07-05 | Heliatek GmbH | Verbindung für fotoaktive organische elektronische bauelemente und fotoaktives organisches elektronisches bauelement enthaltend die verbindung |
| US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
| US11071727B2 (en) | 2018-01-26 | 2021-07-27 | Northwestern University | Therapeutic targeting of proteolytic cleavage of the mixed lineage leukemia gene product (MLL1) by taspase1 using kinase inhibitors |
| WO2025085819A1 (en) * | 2023-10-18 | 2025-04-24 | Washington University | Kinase inhibitor compositions and related methods for the treatment of a disease |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6846839B1 (en) * | 1995-06-07 | 2005-01-25 | Sugen, Inc. | Methods for treating diseases and disorders related to unregulated angiogenesis and/or vasculogenesis |
| US5880141A (en) * | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| US20030119895A1 (en) * | 1998-12-23 | 2003-06-26 | Pharmacia Corporation | Methods using a combination of a 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia |
| AR034118A1 (es) * | 2000-02-15 | 2004-02-04 | Sugen Inc | Compuestos de 2-indolinonas sustituidas con pirroles inhibidoras de proteinquinasas; sus composiciones farmaceuticas e intermediarios de sintesis |
| AR042586A1 (es) * | 2001-02-15 | 2005-06-29 | Sugen Inc | 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa |
| WO2002096361A2 (en) * | 2001-05-30 | 2002-12-05 | Sugen, Inc. | 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors |
| US7105563B2 (en) * | 2003-10-24 | 2006-09-12 | Schering Aktiengesellschaft | Indolinone derivatives and their use in treating disease-states such as cancer |
| JP2007084494A (ja) * | 2005-09-22 | 2007-04-05 | Oncorex Inc | Ｐｉｍ−１活性阻害剤 |
| US8367664B2 (en) * | 2006-01-24 | 2013-02-05 | Allergan, Inc. | Substituted 3-(5-membered unsaturated heterocyclyl-1, 3-dihydro-indol-2-one's and derivatives thereof as kinase inhibitors |
| CA2639913A1 (en) | 2006-01-25 | 2007-08-02 | Synta Pharmaceutical Corp. | Phenyl and pyridyl compounds for inflammation and immune-related uses |
| PL1973910T3 (pl) * | 2006-01-27 | 2013-11-29 | Shanghai hengrui pharmaceutical co ltd | Pirolo[3,2-c]pirydyn-4-onowo-2-indolinonowe inhibitory kinazy białkowej |
-
2009
- 2009-06-30 WO PCT/US2009/049318 patent/WO2010002933A1/en not_active Ceased
- 2009-06-30 JP JP2011516831A patent/JP2011526917A/ja active Pending
- 2009-06-30 CA CA2729745A patent/CA2729745A1/en not_active Abandoned
- 2009-06-30 KR KR1020117002316A patent/KR20110025996A/ko not_active Withdrawn
- 2009-06-30 AU AU2009267048A patent/AU2009267048A1/en not_active Withdrawn
- 2009-06-30 BR BRPI0914942-2A patent/BRPI0914942A2/pt not_active IP Right Cessation
- 2009-06-30 US US12/495,666 patent/US8124649B2/en not_active Expired - Fee Related
- 2009-06-30 EP EP09774383A patent/EP2307421A4/en not_active Withdrawn
- 2009-06-30 CN CN2009801336712A patent/CN102137866A/zh active Pending
- 2009-06-30 MX MX2011000150A patent/MX2011000150A/es not_active Application Discontinuation
-
2010
- 2010-12-29 IL IL210355A patent/IL210355A0/en unknown
-
2011
- 2011-01-20 ZA ZA2011/00539A patent/ZA201100539B/en unknown
-
2012
- 2012-01-20 US US13/354,563 patent/US20120190669A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2729745A1 (en) | 2010-01-07 |
| US20120190669A1 (en) | 2012-07-26 |
| WO2010002933A1 (en) | 2010-01-07 |
| US20100041635A1 (en) | 2010-02-18 |
| CN102137866A (zh) | 2011-07-27 |
| US8124649B2 (en) | 2012-02-28 |
| AU2009267048A1 (en) | 2010-01-07 |
| JP2011526917A (ja) | 2011-10-20 |
| ZA201100539B (en) | 2011-11-30 |
| IL210355A0 (en) | 2011-03-31 |
| MX2011000150A (es) | 2011-04-05 |
| KR20110025996A (ko) | 2011-03-14 |
| EP2307421A1 (en) | 2011-04-13 |
| EP2307421A4 (en) | 2011-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2288375T3 (da) | Pegylerede insulin-lispro-forbindelser | |
| BRPI0920707A2 (pt) | compostos | |
| DK2242759T3 (da) | Forbindelser | |
| BRPI0921327A2 (pt) | Combinação de herbicida-protetor | |
| DK2340021T3 (da) | Substituerede pyrrolidin-2-carboxamider | |
| EP2376493A4 (en) | DIHYDROPYRIMIDOPYRIMIDINDERIVAT | |
| EP2380877A4 (en) | PYRIDINE-3-CARBONSÄUREAMIDDERIVAT | |
| BRPI0907376A2 (pt) | Fotobiorretador | |
| FIC20240018I1 (fi) | Vamoroloni | |
| BRPI0915064A2 (pt) | derivados de qunoxalinadiona | |
| SMT201600045B (it) | Composti tetraciclinici c7-fluoro sostituiti | |
| BRPI0913832A2 (pt) | derivados de pirrolopiridinilpirimidin-2-ilamina | |
| EP2336132A4 (en) | MORPHOLINPURINDERIVAT | |
| BRPI0818338A2 (pt) | Composto de pirimidil indolina | |
| DK2297162T3 (da) | Forbindelser | |
| PT2265578E (pt) | Derivados de azetidina | |
| IL210355A0 (en) | Oxindole compounds | |
| BRPI0922098A2 (pt) | composto inorgânicos | |
| BRPI0907522A2 (pt) | biarlamidas | |
| BRPI0913234A2 (pt) | derivados de tiazolilpiperidina | |
| BRPI0922652A2 (pt) | Derivados de quinazolinamida | |
| BRPI0915562A2 (pt) | tamis melhorado | |
| BRPI0916432A2 (pt) | compostos | |
| BRPI0915442A2 (pt) | tamis melhorado | |
| BRPI0909634A2 (pt) | 2-aminoquinolinas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A E 6A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |